A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors

• Published in: Journal of clinical oncology Vol. 28; no. 15_suppl; p. 3014
• Main Authors: Weekes, C. D., Hegde, P., Xin, Y., Yu, R., Xiang, H., Beeram, M., Gore, L., Brachmann, R. K., Patnaik, A.
• Format: Journal Article
• Language: English
• Published: 20.05.2010

Abstract only